Given the emerging efficacy of these agents, PD-1/PD-L1 expression holds promise as a potential biomarker for selecting sarcoma patients who may benefit from immunotherapy, thus worth investigating in sarcoma cases. This evidence concerns the gene CD274 and sarcoma.